#Gilead Sciences

#2023USCHA was a Love Letter to Black Women—and a joyous family reunion for the HIV community. [VIDEOS]

The “5 Years, 5 Voices” series celebrates the fifth anniversary of Gilead Sciences’ COMPASS initiative to fund HIV efforts in the South.

Internal documents show Gilead held off on developing new therapies, such as Descovy, a potentially less toxic version of Truvada.

The $3.6 billion antitrust court case cleared Gilead Sciences and Teva of delaying the release of generic Truvada and other HIV meds.

A jury in May ruled in favor of Gilead Sciences, maker of HIV prevention pills. Now the government wants a judge to overturn the verdict.

The 38th annual AIDS Walk New York supports GMHC and other HIV and AIDS groups. Plus: Don’t miss the Latex Ball!

Read the complete statement by PrEP4All activists on the “disappointing verdict in ‘U.S. v. Gilead.’”

The battle between the CDC and Gilead over the patent for Truvada and Descovy for HIV prevention is heading to court.

FCAA and AIDSVu collaborate to track philanthropic funding within states, counties and cities targeted by the U.S. plan to end HIV.

Similar declines in PrEP budgets likely hit other HIV clinics that serve uninsured Black, brown and LGBTQ communities. Here’s why.

The new injectable antiretroviral keeps HIV under control, but it still needs an equally long-acting partner.

Broadway legend André De Shields and other HIV advocates appear in the commercial to support modernizing HIV crime laws.

Long-acting injectable Sunlenca (lenacapavir) is indicated for heavily treatment-experienced people with limited treatment options.

This is an improvement from 36% in 2020, notes this year’s State of HIV Stigma Report and survey from GLAAD.

The U.S. Business Action to End HIV coalition boosts public-private partnerships and spells out six ways companies can fight the epidemic.